Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines.In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Australia, Canada, China, and Hong Kong.Deciphera (NASDAQ: DCPH) is a publicly traded company headquartered in Waltham, Massachusetts. Our state-of-the-art research facility is located in Lawrence, Kansas. We offer an outstanding culture and opportunity for personal and professional growth based on our “PATHS” Core Values:Patients – places the importance of improving the lives of patients and their caregivers at the forefront of every day’s work.Accountability – for our performance and the way we work with coworkers and other stakeholders.Transparency – in our intent and actions to both internal and external stakeholders.Honesty and Integrity – fosters trust and strives to deliver on our and the company’s promises.Stewardship – values and uses wisely the resources and investments provided to the company.